Patient presents for ongoing management of Xarelto (rivaroxaban) therapy.  Reason for Xarelto use includes [specific indication, e.g., atrial fibrillation, deep vein thrombosis, pulmonary embolism, prevention of venous thromboembolism following knee or hip replacement surgery].  Patient reports [current dosage and frequency of Xarelto administration].  Review of systems reveals [positive or pertinent negative findings related to bleeding, bruising, or thromboembolic events, e.g., easy bruising, epistaxis, hematuria, GI bleeding, chest pain, shortness of breath, leg swelling, pain, or redness].  Medication reconciliation performed.  Current medications include Xarelto and [list other medications including over-the-counter drugs and supplements].  Assessment of compliance with Xarelto therapy discussed, including adherence to prescribed dosage and timing.  Potential drug interactions evaluated.  INR not applicable for Xarelto monitoring.  Patient education provided regarding signs and symptoms of bleeding complications, importance of medication compliance, and necessary precautions while on Xarelto therapy.  Discussed the need to avoid nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin unless specifically approved by the prescribing physician.  Reviewed the importance of informing all healthcare providers, including dentists and surgeons, about current Xarelto use.  Patient understands the instructions and demonstrates good comprehension of the treatment plan.  Plan to continue Xarelto at the current dose of [dosage] [frequency].  Follow-up appointment scheduled in [duration] to reassess treatment efficacy and monitor for potential adverse events.  Patient encouraged to contact the clinic immediately if any signs or symptoms of bleeding or thromboembolic events occur.